There appeared to be a treatment effect for OS favoring nab-paclitaxel plus gemcitabine over gemcitabine alone in poor-prognosis subgroups defined by these factors ( HR = 0.612 , P < .001 for CA19-9 level median and HR = 0.81 , P = .079 for NLR > 5 ) .